54 related articles for article (PubMed ID: 23617461)
21. KRAS Mutants Upregulate Integrin β4 to Promote Invasion and Metastasis in Colorectal Cancer.
Choi SH; Kim JK; Chen CT; Wu C; Marco MR; Barriga FM; O'Rourke K; Pelossof R; Qu X; Chang Q; de Stanchina E; Shia J; Smith JJ; Sanchez-Vega F; Garcia-Aguilar J
Mol Cancer Res; 2022 Aug; 20(8):1305-1319. PubMed ID: 35394541
[TBL] [Abstract][Full Text] [Related]
22. Integrin β4 reduces DNA damage‑induced p53 activation in colorectal cancer.
Wu J; Zhao R; Lin J; Liu B
Oncol Rep; 2018 Oct; 40(4):2183-2192. PubMed ID: 30106452
[TBL] [Abstract][Full Text] [Related]
23. Curcumin Prevents Palmitoylation of Integrin β4 in Breast Cancer Cells.
Coleman DT; Soung YH; Surh YJ; Cardelli JA; Chung J
PLoS One; 2015; 10(5):e0125399. PubMed ID: 25938910
[TBL] [Abstract][Full Text] [Related]
24. Integrin β4 as a Potential Diagnostic and Therapeutic Tumor Marker.
Yang H; Xu Z; Peng Y; Wang J; Xiang Y
Biomolecules; 2021 Aug; 11(8):. PubMed ID: 34439865
[TBL] [Abstract][Full Text] [Related]
25. [Immunohistological study for the ras oncogene products in colorectal cancer].
Nakago S
Nihon Shokakibyo Gakkai Zasshi; 1990 Oct; 87(10):2358-65. PubMed ID: 2250377
[TBL] [Abstract][Full Text] [Related]
26. Phenotypic discordance between siblings with junctional epidermolysis bullosa-pyloric atresia.
Verma KP; Robertson SJ; Winship IM
Clin Exp Dermatol; 2020 Aug; 45(6):793-795. PubMed ID: 32359087
[No Abstract] [Full Text] [Related]
27. Revising the Role of Integrin Subunit β4 Expression in Colon Cancer Progression and Survival.
Rademaker E; Bastiaannet E; Oosting J; Dekker-Ensink NG; Kuppen PJK; de Miranda NFCC; Liefers GJ
J Gastrointest Cancer; 2023 Mar; 54(1):147-154. PubMed ID: 35112314
[TBL] [Abstract][Full Text] [Related]
28. Analysis on the relevance of asthma susceptibility with the alteration of integrin β 4 expression.
Xiang Y; Zhou XY; Tan YR; Tan ML; Liu HJ; Liu C; Qu XP; Qin XQ
PLoS One; 2014; 9(4):e95533. PubMed ID: 24740264
[TBL] [Abstract][Full Text] [Related]
29. Leukaemic escape routes.
Dart A
Nat Rev Cancer; 2018 Oct; 18(10):599. PubMed ID: 30158650
[No Abstract] [Full Text] [Related]
30. Role of Integrins in Resistance to Therapies Targeting Growth Factor Receptors in Cancer.
Cruz da Silva E; Dontenwill M; Choulier L; Lehmann M
Cancers (Basel); 2019 May; 11(5):. PubMed ID: 31109009
[TBL] [Abstract][Full Text] [Related]
31. Epidermal growth factor-mediated Rab25 pathway regulates integrin β1 trafficking in colon cancer.
Hong KS; Jeon EY; Chung SS; Kim KH; Lee RA
Cancer Cell Int; 2018; 18():32. PubMed ID: 29515334
[TBL] [Abstract][Full Text] [Related]
32. Biomarkers predicting resistance to epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer with wild-type KRAS.
Liu J; Hu J; Cheng L; Ren W; Yang M; Liu B; Xie L; Qian X
Onco Targets Ther; 2016; 9():557-65. PubMed ID: 26869800
[TBL] [Abstract][Full Text] [Related]
33. Keratins Stabilize Hemidesmosomes through Regulation of β4-Integrin Turnover.
Seltmann K; Cheng F; Wiche G; Eriksson JE; Magin TM
J Invest Dermatol; 2015 Jun; 135(6):1609-1620. PubMed ID: 25668239
[TBL] [Abstract][Full Text] [Related]
34. Polymorphisms in cyclooxygenase-2 and epidermal growth factor receptor are associated with progression-free survival independent of K-ras in metastatic colorectal cancer patients treated with single-agent cetuximab.
Lurje G; Nagashima F; Zhang W; Yang D; Chang HM; Gordon MA; El-Khoueiry A; Husain H; Wilson PM; Ladner RD; Mauro DJ; Langer C; Rowinsky EK; Lenz HJ
Clin Cancer Res; 2008 Dec; 14(23):7884-95. PubMed ID: 19047118
[TBL] [Abstract][Full Text] [Related]
35. K-ras mutations and benefit from cetuximab in advanced colorectal cancer.
Karapetis CS; Khambata-Ford S; Jonker DJ; O'Callaghan CJ; Tu D; Tebbutt NC; Simes RJ; Chalchal H; Shapiro JD; Robitaille S; Price TJ; Shepherd L; Au HJ; Langer C; Moore MJ; Zalcberg JR
N Engl J Med; 2008 Oct; 359(17):1757-65. PubMed ID: 18946061
[TBL] [Abstract][Full Text] [Related]
36. Controversies in antiepidermal growth factor receptor therapy in metastatic colorectal cancer.
Woo J; Palmisiano N; Tester W; Leighton JC
Cancer; 2013 Jun; 119(11):1941-50. PubMed ID: 23504768
[TBL] [Abstract][Full Text] [Related]
37. Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab.
Khambata-Ford S; Garrett CR; Meropol NJ; Basik M; Harbison CT; Wu S; Wong TW; Huang X; Takimoto CH; Godwin AK; Tan BR; Krishnamurthi SS; Burris HA; Poplin EA; Hidalgo M; Baselga J; Clark EA; Mauro DJ
J Clin Oncol; 2007 Aug; 25(22):3230-7. PubMed ID: 17664471
[TBL] [Abstract][Full Text] [Related]
38. Understanding the predictive role of K-ras for epidermal growth factor receptor-targeted therapies in colorectal cancer.
Ramos FJ; Macarulla T; Capdevila J; Elez E; Tabernero J
Clin Colorectal Cancer; 2008 Dec; 7 Suppl 2():S52-7. PubMed ID: 19064407
[TBL] [Abstract][Full Text] [Related]
39. Role of β4 integrin in HER-3-negative, K-RAS wild-type metastatic colorectal tumors receiving cetuximab.
Scartozzi M; Giampieri R; Loretelli C; Mandolesi A; del Prete M; Biagetti S; Alfonsi S; Faloppi L; Bianconi M; Bittoni A; Bearzi I; Cascinu S
Future Oncol; 2013 Aug; 9(8):1207-14. PubMed ID: 23617461
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
